Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rivastigmine tartrate
Drug ID BADD_D01956
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status approved; investigational
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D02558
MeSH ID D000068836
PubChem ID 6918078
TTD Drug ID D0WY5Q
NDC Product Code 0904-7107; 53104-7571; 33342-091; 62332-064; 62332-066; 71209-013; 71209-014; 71209-015; 72241-012; 33342-090; 51991-795; 55111-352; 62756-148; 65862-650; 46708-063; 46708-064; 55111-354; 62135-902; 62756-145; 62756-147; 60687-574; 62135-901; 62756-146; 72241-014; 75834-133; 65862-612; 65862-648; 33342-092; 62135-903; 72241-011; 75834-136; 49706-1826; 65862-651; 46708-066; 55111-066; 55111-353; 55111-355; 62332-063; 65862-649; 71209-012; 72241-013; 75834-135; 62704-0122; 65372-1152; 33342-089; 51991-793; 50379-0012; 46708-065; 51991-794; 62135-900; 62332-065; 75834-134; 51991-796
UNII 9IY2357JPE
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C18H28N2O8
CAS Registry Number 129101-54-8
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C.C(C(C(=O)O)O)(C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Varicose vein24.10.04.001--Not Available
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasculitis24.12.04.027; 10.02.02.006--
Vertigo17.02.12.002; 04.04.01.003--
Vestibular disorder17.02.02.008; 04.04.02.001--
Viral infection11.05.04.001--Not Available
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Musculoskeletal disorder15.03.05.025--Not Available
Sudden cardiac death08.04.01.008; 02.03.04.016--Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Application site eczema23.03.04.015; 12.07.01.019; 08.02.01.019--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Large intestine polyp16.05.02.006; 07.20.01.010--Not Available
Acute coronary syndrome02.02.02.015; 24.04.04.011--Not Available
Oesophageal rupture12.01.17.015; 07.04.05.005--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Cerebral disorder17.02.10.017--Not Available
Haemorrhage24.07.01.002--Not Available
Faecaloma07.01.03.004--Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Dermatitis psoriasiform23.03.14.004--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.012--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
The 13th Page    First    Pre   13 14 15    Next   Last    Total 15 Pages